To give some idea of the sheer size of Johnson & Johnson, a glance at its reported sales figure is revealing. In the fourth ...

The launch of DeepSeek’s cost-effective AI assistant in China, has sent shockwaves through global markets, leading to a ...

All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time.

Good morning and welcome to Johnson & Johnson's Fourth Quarter 2024 ... pumps to treat pediatric patients and FDA clearance of Shockwave's Javelin Peripheral IVL Catheter for the treatment of ...

Here's the skinny on that quarter and whether the rest of the year will be healthy enough to rank the company's stock as a buy. To give some idea of the sheer size of Johnson & Johnson ...

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...

Johnson & Johnson (NYSE: JNJ) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the vaunted, 30-company Dow Jones Industrial Average that year. Yet, if the ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

The purchase will allow Johnson & Johnson to delve further into ... including a $13.1 billion deal for Shockwave Medical in 2024. Antitrust laws, designed to promote competition and prevent ...

Johnson & Johnson remains a "Buy" for its stability and consistent ... we must point out that this is not just organic growth. For example, the Shockwave acquisition contributed to the high ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus away from enormous takeovers to single-digit billion buy outs.